NewLimit
South San Francisco
About NewLimit
NewLimit is a biotechnology company that focuses on extending human healthspan through epigenetic reprogramming of cells. The company develops innovative medicines aimed at restoring youthful function in aging cells, targeting age-related diseases. NewLimit employs cutting-edge research to explore the potential of cellular rejuvenation, contributing to advancements in biomedicine. By utilizing epigenetic techniques, the company seeks to provide solutions that enhance the quality of life as individuals age. Its approach represents a significant shift in how age-related conditions are understood and treated, paving the way for new therapeutic options.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $247.2M
- Funding stage: Early Stage Venture
- Last round: Convertible Note (Oct 2025)
- Website: newlimit.com
Industries & Categories
Biotechnology, Clinical Trials, Health Care
Social Profiles
Canonical: https://fsome.com/organization/newlimit-4671 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.